DVM

VetChip Wins 2024 Purina Pet Care Innovation Grand Prize

Retrieved on: 
Thursday, March 21, 2024
Microalgae, Shark, Dentistry, DVM, Organization, Exercise, Television, Pet, Food, Global Pet Expo, Shark Tank, Veterinarian, Cat, Corporation, Pet industry

ORLANDO, Fla., March 21, 2024 /PRNewswire/ -- VetChip was selected as the grand prize winner of the 2024 Pet Care Innovation Prize, earning $25,000 and support from the pet care experts at Purina. VetChip was one of five pet care startups from across the U.S., Canada, and Australia that pitched their businesses to pet industry influencers and investors at Global Pet Expo, the pet care industry's biggest trade show. The biotechnology company is dedicated to improving animal health and welfare through pioneering technology that monitors, analyzes, and detects pet health issues. The VetChip is implanted to gather data and alert pet owners via an app if potential issues or signs of illness or injury are detected, allowing for faster diagnosis and treatment.

Key Points: 
  • ORLANDO, Fla., March 21, 2024 /PRNewswire/ -- VetChip was selected as the grand prize winner of the 2024 Pet Care Innovation Prize , earning $25,000 and support from the pet care experts at Purina.
  • "We are absolutely thrilled to have our revolutionary biosensor achievements recognized through the Pet Care Innovation Prize 2024," said VetChip co-founder Garnett Hall, DVM.
  • The 2024 class of Pet Care Innovation Prize winners represents some of the best innovation happening in the $136.8 billion* pet care industry.
  • The Pet Care Innovation Prize was created to support and connect with early stage pet care startups that are currently in market with an innovative business addressing pet and pet owner needs in the areas of pet health and wellness, services, technology, and food, treats or litter.

PSA: As Pandemic Pets Enter New Life Stages, Petco Shares Tips for Supporting Pet Health and Wellness

Retrieved on: 
Wednesday, March 20, 2024
ASPCA, Health, DVM, Database, Pet, Growth, Bed, COVID-19, SAN, Infection, Vaccine, Calcium, Social anxiety, Human, MBA, Diet, Dog, Skin, Cognition, Safety, Cat, Parent, Hand, Vaccination, Pet industry

SAN DIEGO, March 20, 2024 /PRNewswire/ -- Four years since the onset of COVID-19, puppies and kittens adopted during the pandemic are now entering adulthood and pets adopted as adults are approaching their senior years. As a partner in complete pet care, Petco Health and Wellness Company Inc. (Nasdaq: WOOF) is sharing veterinarian-recommended tips for supporting pets through life stage transitions.

Key Points: 
  • As a partner in complete pet care, Petco Health and Wellness Company Inc. (Nasdaq: WOOF) is sharing veterinarian-recommended tips for supporting pets through life stage transitions.
  • It's critically important that pet parents understand the varying life stages and how they can help their pets live their healthiest, happiest lives at each milestone."
  • As pets enter their senior years, a trusted veterinarian can diagnose and treat issues to help pets live longer, healthier lives.
  • For more information on supporting pet health and wellness through life stage transitions, visit a Petco pet care center or petco.com.

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

Retrieved on: 
Wednesday, March 13, 2024
DVM, Head, Q&A, Entrepreneurship, Immunotherapy, Patient, Triple-negative breast cancer, Immunology, Geisel School of Medicine, Columbia University, Cancer, Doctor of Philosophy, MD, Lung cancer, Yale School of Medicine, Neoplasm, Physician, VISTA, Management

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).

Key Points: 
  • SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
  • High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors.
  • Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
  • The symposium will explore the important role of VISTA in cancer immunotherapy.

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

Retrieved on: 
Wednesday, March 13, 2024
DVM, Head, Q&A, Entrepreneurship, Immunotherapy, Patient, Triple-negative breast cancer, Immunology, Geisel School of Medicine, Columbia University, Cancer, Doctor of Philosophy, MD, Lung cancer, Yale School of Medicine, Neoplasm, Physician, VISTA, Management

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).

Key Points: 
  • SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
  • High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors.
  • Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
  • The symposium will explore the important role of VISTA in cancer immunotherapy.

Modern Animal Expands in Los Angeles, Opens Tenth State-of-the-Art Veterinary Clinic to Elevate the Pet Care Experience

Retrieved on: 
Monday, March 11, 2024
Roger Hawkins (drummer), Veterinarian, Dental care, Pet, Cat, DVM, Dog, Veterinary medicine, La Brea Avenue

LOS ANGELES, March 11, 2024 /PRNewswire/ -- Modern Animal, a pioneering veterinary medicine company dedicated to redefining pet care, is thrilled to announce the grand opening of its tenth state-of-the-art clinic in Los Angeles located on La Brea Avenue.

Key Points: 
  • LOS ANGELES, March 11, 2024 /PRNewswire/ -- Modern Animal, a pioneering veterinary medicine company dedicated to redefining pet care, is thrilled to announce the grand opening of its tenth state-of-the-art clinic in Los Angeles located on La Brea Avenue.
  • With a mission to revolutionize the veterinary experience for both pets and their owners, Modern Animal's latest clinic offers high-quality primary and urgent care to dogs and cats while providing pet owners with unparalleled service and convenience.
  • "Our new clinic on La Brea represents a significant milestone in our journey to redefine pet care across the region.
  • In addition to its comprehensive veterinary services, the new clinic also features a range of amenities aimed at enhancing the overall pet care experience.

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Retrieved on: 
Monday, February 26, 2024
SAN, DVM, Lupus, PD-1, Cell, Agreement, Immune system

BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), pursuant to which Otsuka acquired iBio’s assets related to its early-stage programmed cell death protein 1 (“PD-1” ) agonist program. The transaction closed on February 25, 2024.

Key Points: 
  • BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), pursuant to which Otsuka acquired iBio’s assets related to its early-stage programmed cell death protein 1 (“PD-1” ) agonist program.
  • Under the terms of the Agreement, iBio will receive an upfront payment of $1.0 million in cash at closing.
  • However, unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists, like the one iBio is selling to Otsuka, are difficult to find.
  • At the same time, it provides a path forward for the PD-1 agonist program via further development by Otsuka.”

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

Retrieved on: 
Monday, February 19, 2024
Veterinarian, Doctor of Philosophy, Livestock, Artificial intelligence, Boehringer, Intelligence, DVM, Health, Animal, Farmer, Limp, Eye, Horse, Boehringer Ingelheim, Smartphone, Diagnosis, Movement, Human, Boehringer Ingelheim Animal Health, Gait, Partnership, Veterinary medicine

A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.

Key Points: 
  • A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses.
  • This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.
  • Changes in gait and signs of lameness can be less pronounced at first and difficult to detect.
  • Through this collaboration, Boehringer will support the introduction of the pioneering Sleip app to the veterinary community, making this technology even more accessible.

Alen Air Purifiers are Transforming Home Health to Fight Rising Indoor Air Quality Dangers

Retrieved on: 
Thursday, March 7, 2024
Residential Building & Real Estate, Consumer Electronics, Technology, Construction & Property, Health, General Health, Specialty, Retail, Family, Home Goods, Consumer, Pet, Air pollution, Soot, Atmosphere, Alen, Dander, Ammonia, Respiratory system, Volatile organic compound, DVM, Natural gas, Carbon monoxide, Dizziness, Asthma, Harvard University, NO2, HEPA, Allergy, Risk, Atmosphere of Earth, Saliva, Benzene, Cleaning, Nitrogen dioxide, Death, Spore, Headache, EPA, Allergen, Urine, Organic compound, Ventilation, Pollen, AAFA, Human, Methane

The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.

Key Points: 
  • The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.
  • “The dangers of poor indoor air quality are not just invisible – they silently jeopardize our health, amplifying the risk of respiratory issues, allergies and long-term health complications,” said Alen CEO, Warburg Lee.
  • Alen air purifiers with HEPA fresh filtration capture fine particles, including ash, soot and VOCs, effectively removing them from the indoor air and reducing exposure to harmful pollutants and allergens like pollen, pet dander, and mold spores, providing symptom relief and improving overall indoor air quality.
  • Addressing these sources of indoor air pollution typically involves implementing strategies such as improving ventilation, using air purifiers with HEPA filters like Alen, and reducing or eliminating the use of products with harmful chemicals.

National Animal Supplement Council Announces Publication of Landmark Safety Study of Cannabidiol Products in Healthy Dogs

Retrieved on: 
Tuesday, March 5, 2024
Cannabis, Retail, White House, Federal Government, Pets, State, Local, Research, Other Policy Issues, Convenience Store, Consumer, Discount, Variety, Science, Veterinary, Public Policy, Government, General Health, Natural Resources, Other Retail, Health, Specialty, Doctor of Philosophy, DVM, SCI, Animal, Female, Dog, Veterinary medicine, Cannabinoid, Veterinarian, NASC, Risk, Frontiers, Cornell College, Human, Male, Cannabidiol, Dietary supplement

The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front.

Key Points: 
  • The National Animal Supplement Council (NASC) today announced that Frontiers in Veterinary Science (Front.
  • has published results from the first-of-its-kind peer-reviewed safety study of cannabidiol products in healthy dogs.
  • In the study, different cannabinoids were well tolerated in healthy male and female dogs when dosed for 90 consecutive days with a 14-day recovery period.
  • “These data demonstrate that different cannabidiols are safe for long-term use in healthy dogs when given at the dose studied,” said Bill Bookout, NASC President.

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Euronext Paris, IPH, Neoplasm, Engineering, Doctor of Philosophy, AACR, IPHA, DVM, ADC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
  • "We are excited to present our findings on IPH45 at this year's AACR.
  • Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and it exhibits a favorable safety profile in preclinical studies," stated Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.
  • "These promising results underscore the potential of IPH45 and reflect our dedication to pioneering the next wave of cancer treatments through advanced antibody engineering.